Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Biologics Market Forecast: Value Set To Climb From $540.46 Billion To $827.24 Billion
The biologics market has experienced substantial growth in recent years. It is projected to expand from $495.56 billion in 2025 to $540.46 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.1%. The historical growth can be attributed to elements such as limited biologics availability, a reliance on traditional therapies, the increasing prevalence of immune-related disorders, improvements in healthcare infrastructure, and rising physician awareness and prescriptions.
The biologics market is set for significant expansion in the upcoming years, with its size expected to reach $827.24 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.2%. This anticipated growth can be attributed to factors such as the development of new monoclonal antibodies, the increased use of mRNA and viral vector vaccines, the growing adoption of personalized biologic therapies, heightened government support and funding for biologics, and the integration of digital health and patient monitoring platforms. Throughout the forecast period, major trends will include the rising acceptance of monoclonal antibodies and therapeutic proteins, advancements in vaccine development including mRNA and viral vector varieties, the expansion of prescription-based biologics and their distribution through hospital pharmacies, a sharpened focus on personalized medicine and targeted biologic treatments, and the integration of biologics with advanced healthcare solutions and patient oversight systems.
Get A Free Sample Report With In-Depth Market Insights:
Biologics Market Growth Backed By Core Demand Fundamentals
The global biologics market is experiencing substantial growth, driven by the escalating demand for personalized medicine. This medical approach, also known as precision medicine, customizes healthcare and treatment plans to align with the unique characteristics of each patient. Personalized medicine facilitates the customization of biological treatments to a patient’s specific genetic and clinical profile, thereby transforming the healthcare landscape. For instance, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from six in 2022. Therefore, the increasing demand for personalized medicine is a key driver for the growth of the biologics market going forward.
Biologics Market Segmentation: How Does The Market Break Down By Category?
The biologics market covered in this report is segmented –
1) By Type: Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines
2) By Drug Classification: Branded Drugs, Generic Drugs
3) By Route Of Administration: Oral, Other Route Of Administration
4) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies Or Drug Stores, Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies (MAbs): Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Therapeutic Proteins: Hormones, Enzymes, Cytokines, Fusion Proteins
3) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, mRNA Vaccines, Viral Vector Vaccines
Biologics Market Growth Trends Reshaping The Competitive Landscape
Companies within the biologics market are prioritizing the creation of novel products, including biosimilars, to offer more economical options compared to existing biologic treatments. These biosimilar products closely resemble an already sanctioned reference biologic, demonstrating negligible variations in their safety, effectiveness, or overall quality, thereby contributing to lower treatment expenses and broader patient accessibility to cutting-edge therapies. An illustrative example is the launch of Nepexto, a biosimilar version of Enbrel (etanercept), by Biocon Biologics, a division of the India-based biopharmaceutical firm Biocon Limited, in Australia during July 2025. Nepexto functions as a fusion-protein biologic, specifically engineered to block tumor necrosis factor-alpha (TNF-a), which is a crucial inflammatory agent involved in various autoimmune diseases. This product comprises a recombinant DNA-derived protein, mirroring the binding action of the initial etanercept molecule, thus ensuring similar efficacy and safety while simultaneously improving treatment accessibility. Its distinguished characteristics encompass substantial biosimilarity supported by extensive clinical evidence, official regulatory clearances, and a well-established distribution network facilitated by its local collaborator, Generic Health, positioning it as an effective choice for the ongoing management of conditions like rheumatoid arthritis, psoriasis, and ankylosing spondylitis.
Biologics Market Competitive Overview And Top Companies
Major companies operating in the biologics market are Merck & Co. Inc., AbbVie Inc., F. Hoffmann-La Roche AG, Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb Company, Sanofi S.A., GlaxoSmithKline Plc., Eli Lilly and Company, Amgen Inc., Shanghai Fosun Pharmaceuticals, Bayer AG, Novartis AG, BiosanaPharma, WuXi, Teva UK Limited, AstraZeneca, Abbott Laboratories, Vectura Group, Fujifilm, Lonza, Seqens, Piramal Pharma Solutions, Corden Pharma, Procos SpA and BSP Pharmaceuticals., Microgen, Geropharm, Valenta, NovaMedica, SynBi, Rani Therapeutics, Enteris BioPharma, Allena Pharmaceuticals, Biogen Inc., Emisphere Technologies Inc., Apotex, Gilead Sciences
View The Full Biologics Market Report:
Biologics Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the biologics market in 2025. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
